{"gene":"ISG20L2","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":2010,"finding":"ISG20L2 (closely related to ISG20) did NOT inhibit HCV replication when overexpressed, in contrast to ISG20 which requires its exonuclease activity for antiviral effects. This negative result distinguishes ISG20L2 from its paralog ISG20 in antiviral function.","method":"Ectopic overexpression assay in cell culture with HCV replication readout","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single overexpression experiment, replicated across multiple viruses for ISG20, but ISG20L2 result is a defined negative finding from a peer-reviewed study","pmids":["21036379"],"is_preprint":false},{"year":2012,"finding":"ISG20L2 co-immunoprecipitates with preribosomal complexes in human cells, sharing a significant number of components with complexes described for nucleophosmin, SBDS, and NIP7, indicating ISG20L2 associates with pre-ribosome complexes involved in ribosome biogenesis.","method":"Co-immunoprecipitation followed by mass spectrometry (proteomic characterization of preribosomal complexes)","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP/MS from a single lab, mentions ISG20L2 as part of a broader preribosome complex study; no direct functional mutagenesis of ISG20L2 in this paper","pmids":["22540864"],"is_preprint":false},{"year":2022,"finding":"ISG20L2 directly binds bortezomib (confirmed by surface plasmon resonance) and competes with PSMB5 for bortezomib binding (shown by biotinylated bortezomib pull-down), thereby attenuating proteasome inhibition and conferring bortezomib resistance in multiple myeloma cells both in vitro and in vivo.","method":"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain- and loss-of-function studies in vitro and in vivo","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding confirmed by SPR (biochemical assay), competitive pull-down, and functional rescue/knockdown in both cell and animal models in a single study with multiple orthogonal methods","pmids":["36040812"],"is_preprint":false},{"year":2023,"finding":"ISG20L2, a 3'-5' exoribonuclease, is upregulated in T cells upon TCR and IFN type I stimulation and degrades uridylated miRNA substrates preferentially. ISG20L2 silencing increases basal CD69 expression and IL-2 secretion but impairs CD25 upregulation, CD3 synaptic accumulation, MTOC translocation toward the APC during immune synapse formation, and controls expression of immunoregulatory molecules (AHR, NKG2D, CTLA-4, CD137, TIM-3, PD-L1, PD-1).","method":"ISG20L2 siRNA knockdown and CRISPR knockout in T cells; flow cytometry for surface markers; ELISA for cytokines; confocal microscopy for immune synapse; exonuclease substrate specificity assays","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal functional assays (KO, flow cytometry, microscopy, enzymatic substrate assay) from a single lab","pmids":["37646974"],"is_preprint":false},{"year":2024,"finding":"ISG20L2 is a DEDDh-motif 3'-5' exonuclease involved in 18S pre-rRNA maturation by removing the ITS1 region. Crystal structure at 2.9 Å resolution revealed a typical αβα fold with catalytic residues Asp183, Glu185, Asp267, His322, and Asp327 forming the DEDDh motif. Mutagenesis mapped RNA substrate-binding residues and confirmed catalytic mechanism. Loss of ISG20L2 impairs ribosome biogenesis and cell proliferation.","method":"Crystal structure determination (2.9 Å), active-site mutagenesis, cellular loss-of-function assays, pre-rRNA processing assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure, active-site mutagenesis, and functional cellular assays all in one rigorous study, establishing catalytic mechanism and substrate","pmids":["38153123"],"is_preprint":false},{"year":2025,"finding":"ISG20L2, a vertebrate-specific DEDDh RNase T superfamily 3'-5' exoribonuclease, is critical for efficient removal of the 3' external transcribed spacer (3'ETS) from pre-rRNA, trimming of ITS1 after endonucleolytic cleavage at site 2, and contributes to 3' processing of U8 snoRNA precursor, thereby contributing to maturation of both 18S and 28S rRNA 3' ends and formation of large ribosomal subunits. ISG20L2 inactivation leads to accumulation of 3'-extended pre-rRNAs and disorganization of the peripheral dense fibrillar component of the nucleolus.","method":"Loss-of-function experiments (inactivation), 3'-RACE high-throughput sequencing, nucleolar morphology analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function combined with high-throughput 3'-RACE sequencing providing nucleotide-resolution mapping of processing steps, with structural/compartment imaging, single rigorous study with multiple orthogonal methods","pmids":["41261865"],"is_preprint":false},{"year":2025,"finding":"ISG20L2 promotes lung adenocarcinoma cell proliferation and invasion by modulating NKX2-1 expression, as confirmed by overexpression and depletion studies in A549 cells.","method":"Transient transfection overexpression and siRNA depletion; CCK-8 proliferation assay; Transwell migration/invasion assay; flow cytometry for apoptosis","journal":"Translational cancer research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single transient transfection approach; NKX2-1 regulation mentioned as confirmed by 'cytological experiments' but mechanistic detail is sparse in the abstract","pmids":["40950659"],"is_preprint":false}],"current_model":"ISG20L2 is a nucleolar DEDDh-motif 3'-5' exoribonuclease (crystal structure resolved) that processes multiple pre-rRNA spacers (ITS1, ITS2, 3'ETS) to drive 18S and 28S rRNA maturation and ribosome biogenesis; outside the nucleolus it degrades uridylated miRNAs to regulate T cell activation, and in the cytoplasm it directly binds the proteasome inhibitor bortezomib and competes with PSMB5 to confer drug resistance in multiple myeloma."},"narrative":{"mechanistic_narrative":"ISG20L2 is a vertebrate-specific DEDDh-motif 3'-5' exoribonuclease of the RNase T superfamily that drives ribosome biogenesis through processing of pre-rRNA spacers [PMID:38153123, PMID:41261865]. A 2.9 Å crystal structure established its αβα fold and defined the catalytic DEDDh residues (Asp183, Glu185, Asp267, His322, Asp327), with mutagenesis confirming the catalytic mechanism and mapping RNA substrate-binding residues [PMID:38153123]. Functionally, it removes the ITS1 region during 18S pre-rRNA maturation [PMID:38153123] and is also required for efficient removal of the 3'ETS, ITS1 trimming after cleavage at site 2, and 3' processing of the U8 snoRNA precursor, thereby contributing to maturation of both 18S and 28S rRNA 3' ends; its loss causes accumulation of 3'-extended pre-rRNAs and disorganization of the nucleolar peripheral dense fibrillar component [PMID:41261865]. Consistent with a nucleolar ribosome-biogenesis role, ISG20L2 co-immunoprecipitates with preribosomal complexes sharing components with nucleophosmin-, SBDS-, and NIP7-associated complexes, and its depletion impairs ribosome biogenesis and cell proliferation [PMID:22540864, PMID:38153123]. Beyond the nucleolus, ISG20L2 preferentially degrades uridylated miRNA substrates and is induced in T cells by TCR and type I IFN stimulation, where it shapes activation markers, cytokine output, immune-synapse organization, and expression of immunoregulatory molecules [PMID:37646974]. In the cytoplasm of multiple myeloma cells, ISG20L2 directly binds the proteasome inhibitor bortezomib and competes with PSMB5 for the drug, attenuating proteasome inhibition and conferring bortezomib resistance [PMID:36040812].","teleology":[{"year":2010,"claim":"Tested whether ISG20L2 shares the antiviral exonuclease activity of its paralog ISG20, establishing that the two proteins are functionally distinct.","evidence":"Ectopic overexpression in cell culture with an HCV replication readout","pmids":["21036379"],"confidence":"Medium","gaps":["Negative result from a single overexpression assay does not exclude antiviral roles under other conditions","No catalytic or mechanistic characterization of ISG20L2 performed here"]},{"year":2012,"claim":"Placed ISG20L2 physically within the ribosome biogenesis machinery, the first link to its core function.","evidence":"Co-immunoprecipitation followed by mass spectrometry of preribosomal complexes in human cells","pmids":["22540864"],"confidence":"Medium","gaps":["Association is correlative; no functional mutagenesis of ISG20L2","Does not identify which processing step ISG20L2 catalyzes"]},{"year":2022,"claim":"Revealed a non-canonical cytoplasmic function: direct drug binding that confers proteasome-inhibitor resistance, independent of any RNA role.","evidence":"Biotinylated bortezomib pull-down, surface plasmon resonance, and gain/loss-of-function in multiple myeloma cells and in vivo","pmids":["36040812"],"confidence":"High","gaps":["Structural basis of bortezomib binding by ISG20L2 not resolved","Relationship between this drug-sequestering role and the enzyme's RNase activity unclear"]},{"year":2023,"claim":"Defined a substrate preference (uridylated miRNAs) and an immune-cell role, extending ISG20L2 function beyond the nucleolus.","evidence":"siRNA knockdown and CRISPR knockout in T cells with flow cytometry, ELISA, confocal microscopy, and exonuclease substrate assays","pmids":["37646974"],"confidence":"Medium","gaps":["Direct miRNA targets that mediate the T cell phenotypes not identified","Whether nucleolar pre-rRNA processing contributes to the immune phenotype is not addressed"]},{"year":2024,"claim":"Established the catalytic mechanism and a defined pre-rRNA substrate, converting the prior associative evidence into a mechanistic identity as a DEDDh 3'-5' exonuclease.","evidence":"2.9 Å crystal structure, active-site mutagenesis, and cellular loss-of-function and pre-rRNA processing assays","pmids":["38153123"],"confidence":"High","gaps":["Structure of an RNA-bound complex not determined","Cofactors or partner proteins guiding substrate selection in vivo not defined"]},{"year":2025,"claim":"Mapped the full repertoire of pre-rRNA and snoRNA processing steps ISG20L2 controls at nucleotide resolution and linked its loss to nucleolar architecture defects.","evidence":"Loss-of-function with 3'-RACE high-throughput sequencing and nucleolar morphology analysis","pmids":["41261865"],"confidence":"High","gaps":["Order and regulation of the multiple processing steps not fully resolved","Functional coupling between U8 snoRNA processing and rRNA maturation by ISG20L2 not established"]},{"year":2025,"claim":"Connected ISG20L2 to a cancer-relevant transcriptional output, proposing it promotes lung adenocarcinoma via NKX2-1.","evidence":"Transient overexpression and siRNA depletion in A549 cells with proliferation, invasion, and apoptosis assays","pmids":["40950659"],"confidence":"Low","gaps":["Single transient-transfection approach in one cell line; not independently confirmed","Mechanism linking ISG20L2 exonuclease activity to NKX2-1 regulation is undefined"]},{"year":null,"claim":"How ISG20L2's distinct activities — nucleolar pre-rRNA processing, cytoplasmic miRNA degradation, and bortezomib sequestration — are partitioned and regulated within the same protein remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No model reconciling nucleolar versus cytoplasmic localization and function","Determinants of substrate and drug selectivity not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[3,4,5]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[4]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[3,4]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[1,5]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[4,5]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[4,5]}],"complexes":["preribosome"],"partners":["PSMB5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H9L3","full_name":"Interferon-stimulated 20 kDa exonuclease-like 2","aliases":[],"length_aa":353,"mass_kda":39.2,"function":"3'-> 5'-exoribonuclease involved in ribosome biogenesis in the processing of the 12S pre-rRNA. Displays a strong specificity for a 3'-end containing a free hydroxyl group","subcellular_location":"Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/Q9H9L3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/ISG20L2","classification":"Common Essential","n_dependent_lines":1166,"n_total_lines":1208,"dependency_fraction":0.9652317880794702},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"NPM1","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"RACK1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ISG20L2","total_profiled":1310},"omim":[{"mim_id":"611930","title":"INTERFERON-STIMULATED EXONUCLEASE GENE 20-KD-LIKE 2; ISG20L2","url":"https://www.omim.org/entry/611930"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"testis","ntpm":58.8}],"url":"https://www.proteinatlas.org/search/ISG20L2"},"hgnc":{"alias_symbol":["FLJ12671"],"prev_symbol":[]},"alphafold":{"accession":"Q9H9L3","domains":[{"cath_id":"3.30.420.10","chopping":"180-349","consensus_level":"high","plddt":97.0182,"start":180,"end":349}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H9L3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H9L3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H9L3-F1-predicted_aligned_error_v6.png","plddt_mean":72.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ISG20L2","jax_strain_url":"https://www.jax.org/strain/search?query=ISG20L2"},"sequence":{"accession":"Q9H9L3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H9L3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H9L3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H9L3"}},"corpus_meta":[{"pmid":"21036379","id":"PMC_21036379","title":"Antiviral activities of ISG20 in positive-strand RNA virus infections.","date":"2010","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/21036379","citation_count":84,"is_preprint":false},{"pmid":"34026765","id":"PMC_34026765","title":"Identification of Key Genes With Differential Correlations in Lung Adenocarcinoma.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34026765","citation_count":18,"is_preprint":false},{"pmid":"22540864","id":"PMC_22540864","title":"Proteomic characterization of the human FTSJ3 preribosomal complexes.","date":"2012","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/22540864","citation_count":17,"is_preprint":false},{"pmid":"36040812","id":"PMC_36040812","title":"ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36040812","citation_count":8,"is_preprint":false},{"pmid":"38153123","id":"PMC_38153123","title":"Molecular mechanism of human ISG20L2 for the ITS1 cleavage in the processing of 18S precursor ribosomal RNA.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38153123","citation_count":7,"is_preprint":false},{"pmid":"37646974","id":"PMC_37646974","title":"ISG20L2: an RNA nuclease regulating T cell activation.","date":"2023","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/37646974","citation_count":5,"is_preprint":false},{"pmid":"41261865","id":"PMC_41261865","title":"The 3'-5' exoribonuclease ISG20L2 contributes to 3' terminus maturation of 18S and 28S ribosomal RNAs.","date":"2025","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/41261865","citation_count":1,"is_preprint":false},{"pmid":"40950659","id":"PMC_40950659","title":"ISG20L2 as a driver in the proliferation and invasion of lung adenocarcinoma via NKX2-1 regulation.","date":"2025","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/40950659","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6203,"output_tokens":2037,"usd":0.024582,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8942,"output_tokens":2683,"usd":0.055892,"stage2_stop_reason":"end_turn"},"total_usd":0.080474,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"ISG20L2 (closely related to ISG20) did NOT inhibit HCV replication when overexpressed, in contrast to ISG20 which requires its exonuclease activity for antiviral effects. This negative result distinguishes ISG20L2 from its paralog ISG20 in antiviral function.\",\n      \"method\": \"Ectopic overexpression assay in cell culture with HCV replication readout\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single overexpression experiment, replicated across multiple viruses for ISG20, but ISG20L2 result is a defined negative finding from a peer-reviewed study\",\n      \"pmids\": [\"21036379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ISG20L2 co-immunoprecipitates with preribosomal complexes in human cells, sharing a significant number of components with complexes described for nucleophosmin, SBDS, and NIP7, indicating ISG20L2 associates with pre-ribosome complexes involved in ribosome biogenesis.\",\n      \"method\": \"Co-immunoprecipitation followed by mass spectrometry (proteomic characterization of preribosomal complexes)\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP/MS from a single lab, mentions ISG20L2 as part of a broader preribosome complex study; no direct functional mutagenesis of ISG20L2 in this paper\",\n      \"pmids\": [\"22540864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ISG20L2 directly binds bortezomib (confirmed by surface plasmon resonance) and competes with PSMB5 for bortezomib binding (shown by biotinylated bortezomib pull-down), thereby attenuating proteasome inhibition and conferring bortezomib resistance in multiple myeloma cells both in vitro and in vivo.\",\n      \"method\": \"Biotinylated bortezomib pull-down assay, surface plasmon resonance, gain- and loss-of-function studies in vitro and in vivo\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding confirmed by SPR (biochemical assay), competitive pull-down, and functional rescue/knockdown in both cell and animal models in a single study with multiple orthogonal methods\",\n      \"pmids\": [\"36040812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ISG20L2, a 3'-5' exoribonuclease, is upregulated in T cells upon TCR and IFN type I stimulation and degrades uridylated miRNA substrates preferentially. ISG20L2 silencing increases basal CD69 expression and IL-2 secretion but impairs CD25 upregulation, CD3 synaptic accumulation, MTOC translocation toward the APC during immune synapse formation, and controls expression of immunoregulatory molecules (AHR, NKG2D, CTLA-4, CD137, TIM-3, PD-L1, PD-1).\",\n      \"method\": \"ISG20L2 siRNA knockdown and CRISPR knockout in T cells; flow cytometry for surface markers; ELISA for cytokines; confocal microscopy for immune synapse; exonuclease substrate specificity assays\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal functional assays (KO, flow cytometry, microscopy, enzymatic substrate assay) from a single lab\",\n      \"pmids\": [\"37646974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ISG20L2 is a DEDDh-motif 3'-5' exonuclease involved in 18S pre-rRNA maturation by removing the ITS1 region. Crystal structure at 2.9 Å resolution revealed a typical αβα fold with catalytic residues Asp183, Glu185, Asp267, His322, and Asp327 forming the DEDDh motif. Mutagenesis mapped RNA substrate-binding residues and confirmed catalytic mechanism. Loss of ISG20L2 impairs ribosome biogenesis and cell proliferation.\",\n      \"method\": \"Crystal structure determination (2.9 Å), active-site mutagenesis, cellular loss-of-function assays, pre-rRNA processing assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure, active-site mutagenesis, and functional cellular assays all in one rigorous study, establishing catalytic mechanism and substrate\",\n      \"pmids\": [\"38153123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ISG20L2, a vertebrate-specific DEDDh RNase T superfamily 3'-5' exoribonuclease, is critical for efficient removal of the 3' external transcribed spacer (3'ETS) from pre-rRNA, trimming of ITS1 after endonucleolytic cleavage at site 2, and contributes to 3' processing of U8 snoRNA precursor, thereby contributing to maturation of both 18S and 28S rRNA 3' ends and formation of large ribosomal subunits. ISG20L2 inactivation leads to accumulation of 3'-extended pre-rRNAs and disorganization of the peripheral dense fibrillar component of the nucleolus.\",\n      \"method\": \"Loss-of-function experiments (inactivation), 3'-RACE high-throughput sequencing, nucleolar morphology analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function combined with high-throughput 3'-RACE sequencing providing nucleotide-resolution mapping of processing steps, with structural/compartment imaging, single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"41261865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ISG20L2 promotes lung adenocarcinoma cell proliferation and invasion by modulating NKX2-1 expression, as confirmed by overexpression and depletion studies in A549 cells.\",\n      \"method\": \"Transient transfection overexpression and siRNA depletion; CCK-8 proliferation assay; Transwell migration/invasion assay; flow cytometry for apoptosis\",\n      \"journal\": \"Translational cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single transient transfection approach; NKX2-1 regulation mentioned as confirmed by 'cytological experiments' but mechanistic detail is sparse in the abstract\",\n      \"pmids\": [\"40950659\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ISG20L2 is a nucleolar DEDDh-motif 3'-5' exoribonuclease (crystal structure resolved) that processes multiple pre-rRNA spacers (ITS1, ITS2, 3'ETS) to drive 18S and 28S rRNA maturation and ribosome biogenesis; outside the nucleolus it degrades uridylated miRNAs to regulate T cell activation, and in the cytoplasm it directly binds the proteasome inhibitor bortezomib and competes with PSMB5 to confer drug resistance in multiple myeloma.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ISG20L2 is a vertebrate-specific DEDDh-motif 3'-5' exoribonuclease of the RNase T superfamily that drives ribosome biogenesis through processing of pre-rRNA spacers [#4, #5]. A 2.9 Å crystal structure established its αβα fold and defined the catalytic DEDDh residues (Asp183, Glu185, Asp267, His322, Asp327), with mutagenesis confirming the catalytic mechanism and mapping RNA substrate-binding residues [#4]. Functionally, it removes the ITS1 region during 18S pre-rRNA maturation [#4] and is also required for efficient removal of the 3'ETS, ITS1 trimming after cleavage at site 2, and 3' processing of the U8 snoRNA precursor, thereby contributing to maturation of both 18S and 28S rRNA 3' ends; its loss causes accumulation of 3'-extended pre-rRNAs and disorganization of the nucleolar peripheral dense fibrillar component [#5]. Consistent with a nucleolar ribosome-biogenesis role, ISG20L2 co-immunoprecipitates with preribosomal complexes sharing components with nucleophosmin-, SBDS-, and NIP7-associated complexes, and its depletion impairs ribosome biogenesis and cell proliferation [#1, #4]. Beyond the nucleolus, ISG20L2 preferentially degrades uridylated miRNA substrates and is induced in T cells by TCR and type I IFN stimulation, where it shapes activation markers, cytokine output, immune-synapse organization, and expression of immunoregulatory molecules [#3]. In the cytoplasm of multiple myeloma cells, ISG20L2 directly binds the proteasome inhibitor bortezomib and competes with PSMB5 for the drug, attenuating proteasome inhibition and conferring bortezomib resistance [#2].\",\n  \"teleology\": [\n    {\n      \"year\": 2010,\n      \"claim\": \"Tested whether ISG20L2 shares the antiviral exonuclease activity of its paralog ISG20, establishing that the two proteins are functionally distinct.\",\n      \"evidence\": \"Ectopic overexpression in cell culture with an HCV replication readout\",\n      \"pmids\": [\"21036379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result from a single overexpression assay does not exclude antiviral roles under other conditions\", \"No catalytic or mechanistic characterization of ISG20L2 performed here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed ISG20L2 physically within the ribosome biogenesis machinery, the first link to its core function.\",\n      \"evidence\": \"Co-immunoprecipitation followed by mass spectrometry of preribosomal complexes in human cells\",\n      \"pmids\": [\"22540864\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Association is correlative; no functional mutagenesis of ISG20L2\", \"Does not identify which processing step ISG20L2 catalyzes\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a non-canonical cytoplasmic function: direct drug binding that confers proteasome-inhibitor resistance, independent of any RNA role.\",\n      \"evidence\": \"Biotinylated bortezomib pull-down, surface plasmon resonance, and gain/loss-of-function in multiple myeloma cells and in vivo\",\n      \"pmids\": [\"36040812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of bortezomib binding by ISG20L2 not resolved\", \"Relationship between this drug-sequestering role and the enzyme's RNase activity unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a substrate preference (uridylated miRNAs) and an immune-cell role, extending ISG20L2 function beyond the nucleolus.\",\n      \"evidence\": \"siRNA knockdown and CRISPR knockout in T cells with flow cytometry, ELISA, confocal microscopy, and exonuclease substrate assays\",\n      \"pmids\": [\"37646974\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miRNA targets that mediate the T cell phenotypes not identified\", \"Whether nucleolar pre-rRNA processing contributes to the immune phenotype is not addressed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established the catalytic mechanism and a defined pre-rRNA substrate, converting the prior associative evidence into a mechanistic identity as a DEDDh 3'-5' exonuclease.\",\n      \"evidence\": \"2.9 Å crystal structure, active-site mutagenesis, and cellular loss-of-function and pre-rRNA processing assays\",\n      \"pmids\": [\"38153123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of an RNA-bound complex not determined\", \"Cofactors or partner proteins guiding substrate selection in vivo not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Mapped the full repertoire of pre-rRNA and snoRNA processing steps ISG20L2 controls at nucleotide resolution and linked its loss to nucleolar architecture defects.\",\n      \"evidence\": \"Loss-of-function with 3'-RACE high-throughput sequencing and nucleolar morphology analysis\",\n      \"pmids\": [\"41261865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order and regulation of the multiple processing steps not fully resolved\", \"Functional coupling between U8 snoRNA processing and rRNA maturation by ISG20L2 not established\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected ISG20L2 to a cancer-relevant transcriptional output, proposing it promotes lung adenocarcinoma via NKX2-1.\",\n      \"evidence\": \"Transient overexpression and siRNA depletion in A549 cells with proliferation, invasion, and apoptosis assays\",\n      \"pmids\": [\"40950659\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single transient-transfection approach in one cell line; not independently confirmed\", \"Mechanism linking ISG20L2 exonuclease activity to NKX2-1 regulation is undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ISG20L2's distinct activities — nucleolar pre-rRNA processing, cytoplasmic miRNA degradation, and bortezomib sequestration — are partitioned and regulated within the same protein remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No model reconciling nucleolar versus cytoplasmic localization and function\", \"Determinants of substrate and drug selectivity not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [3, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [1, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"complexes\": [\"preribosome\"],\n    \"partners\": [\"PSMB5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}